Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.67
- Piotroski Score 3.00
- Grade Buy
- Symbol (VRNA)
- Company Verona Pharma plc
- Price $39.03
- Changes Percentage (3.08%)
- Change $1.17
- Day Low $37.67
- Day High $39.25
- Year High $40.13
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $36.00
- High Stock Price Target $42.00
- Low Stock Price Target $26.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.80
- Trailing P/E Ratio -15.16
- Forward P/E Ratio -15.16
- P/E Growth -15.16
- Net Income $-54,369,000
Income Statement
Quarterly
Annual
Latest News of VRNA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising Costs
Over 5,000 unique patients have been prescribed Ohtuvayre, with increasing refills and patient adds. Prescriber trends show a broad range of therapy combinations. Infrastructure for patient access is ...
By Yahoo! Finance | 2 weeks ago -
Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)
On September 11, 2024, Verona Pharma PLC's CFO, Mark Hahn, sold 600,000 shares, now owning 14,339,688 shares. The biopharmaceutical company focuses on respiratory disease therapies....
By Yahoo! Finance | 2 months ago -
Verona Pharma PLC (VRNA) CEO David Zaccardelli Sells 600,000 Shares
David Zaccardelli, CEO of Verona Pharma PLC, recently sold 600,000 shares of the company, bringing his total ownership to 15,250,704 shares. The company focuses on respiratory disease therapies....
By Yahoo! Finance | 2 months ago
